Madrigal Q3 operating expenses $98.5M; FDA Priority Review for resmetirom; $500M October financing

MADRIGAL PHARMACEUTICALS, INC.

2023-Q3 EPS reported -$14.27

FDA accepted NDA for resmetirom, granted Priority Review; PDUFA date March 14, 2024; no advisory committee planned.
Bill Sibold appointed CEO in Sep 2023; previously EVP at Sanofi, led Dupixent launch.
$500M public offering closed Oct 2023; net proceeds $472M for pre-launch activities.
Cash and securities $232.4M as of Sep 30, 2023, prior to October offering.
Q3 2023 operating expenses $98.5M ($71.0M R&D, $27.6M G&A); nine-month total $263.3M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MADRIGAL PHARMACEUTICALS, INC. reported financial results for third quarter 2023.

Period: third quarter 2023
Result: reported results

Exact text from the filing

On November 6, 2023, Madrigal Pharmaceuticals, Inc. (the "Company") issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

MADRIGAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-270884

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.